Literature DB >> 15635961

Antimicrobial resistance of Shigella flexneri serotypes in Israel during a period of three years: 2000-2002.

V Vasilev1, R Japheth, R Yishai, N Andorn.   

Abstract

This is a surveillance study of the antimicrobial resistance of the S. flexneri group in the context of its serotype diversity. It includes 1422 isolates, which were sent to the National Shigella Reference Centre (NSRC) by hospitals and outpatient clinics in Israel during a 3-year period (2000-2002). The strains were identified and classified according to the prevalence and antigenic structure of their serotypes. All samples were checked for resistance to ampicillin (AMP), trimethoprim-sulphamethoxazole (TMP-SMX), ceftriaxone (CRO), tetracycline (TE), nalidixic acid (NAL), and chloramphenicol (C) by the disk diffusion method of Bauer et al. There were significant differences in their resistance to the individual antimicrobials with resistance to AMP, TE and C being lower among the strains of serotype 6 than among those of serotypes 2a and 1b. The resistant phenotypes were also serotype-specific. The similarities both in individual and in phenotype resistance between the rare and the prevalent serotypes (but not serotype 6) may be attributed to their antigenic relatedness. The serospecificity of the antimicrobial resistance was not affected by external factors such as seasonality and source (hospital or outpatient laboratory) of the isolates, and the age and sex of the patients. The serotype-specific approach can assist in properly assessing the problem of the antimicrobial resistance of the Shigella flexneri group and may prove useful for the empirical therapy of shigellosis. The observed interdependency between resistance and the antigenic specificity and relatedness of the S. flexneri serotypes requires additional investigation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15635961      PMCID: PMC2870195          DOI: 10.1017/s0950268804002912

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  4 in total

1.  High genetic stability of integrons in clinical isolates of Shigella spp. of worldwide origin.

Authors:  Véronique Dubois; Marie-Pierre Parizano; Corinne Arpin; Laure Coulange; Marie-Christine Bezian; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

2.  Epidemiology and genetic characterization of Shigella flexneri strains isolated from three paediatric populations in Egypt (2000-2004).

Authors:  S F Ahmed; M S Riddle; T F Wierzba; I Abdel Messih; M R Monteville; J W Sanders; J D Klena
Journal:  Epidemiol Infect       Date:  2006-05-11       Impact factor: 2.451

3.  Extended-spectrum beta-lactamase-producing Shigella strains in Israel, 2000-2004.

Authors:  V Vasilev; R Japheth; R Yishai; N Andorn; L Valinsky; S Navon-Venezia; I Chmelnitsky; Y Carmeli; D Cohen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-03       Impact factor: 3.267

4.  Recent trends in the epidemiology of shigellosis in Israel.

Authors:  D Cohen; R Bassal; S Goren; T Rouach; D Taran; B Schemberg; N Peled; Y Keness; S Ken-Dror; V Vasilev; I Nissan; V Agmon; T Shohat
Journal:  Epidemiol Infect       Date:  2014-02-20       Impact factor: 4.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.